Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant and neoadjuvant therapy for primary GIST

  • Supplement (Special Issue)
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Adjuvant therapy for primary GIST has proven benefit in extending disease free survival. Defined risk factors for recurrent disease are based on GIST size, location, and mitotic rate and provide useful guidelines for selecting patients for adjuvant therapy considerations. Neoadjuvant therapy with tyrosine kinase inhibition has potential usefulness in primary GIST, although not yet as standard of care. Advantages can include tumor downsizing to provide opportunity for less morbid surgical resection as well as to decrease risk of intra-op tumor rupture. These theoretical considerations have not been evaluated in large clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ng EH et al (1992) Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215(1):68–77

    Article  CAS  PubMed  Google Scholar 

  2. DeMatteo RP et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1):51–58

    Article  CAS  PubMed  Google Scholar 

  3. Pierie JP et al (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136(4):383–389

    Article  CAS  PubMed  Google Scholar 

  4. Crosby JA et al (2001) Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 8(1):50–59

    Article  CAS  PubMed  Google Scholar 

  5. Fletcher CD et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 10(2):81–89

    Article  PubMed  Google Scholar 

  6. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23(2):70–83

    Article  PubMed  Google Scholar 

  7. Takahashi T et al (2007) An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 12(5):369–374

    Article  CAS  PubMed  Google Scholar 

  8. Maeda H et al (1992) Requirement of c-kit for development of intestinal pacemaker system. Development 116(2):369–375

    CAS  PubMed  Google Scholar 

  9. Isozaki K et al (1995) Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 109(2):456–464

    Article  CAS  PubMed  Google Scholar 

  10. Furitsu T et al (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92(4):1736–1744

    Article  CAS  PubMed  Google Scholar 

  11. Nagata H et al (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92(23):10560–10564

    Article  CAS  PubMed  Google Scholar 

  12. Hirota S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580

    Article  CAS  PubMed  Google Scholar 

  13. Taniguchi M et al (1999) Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59(17):4297–4300

    CAS  PubMed  Google Scholar 

  14. Joensuu H et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052–1056

    Article  CAS  PubMed  Google Scholar 

  15. Demetri GD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  CAS  PubMed  Google Scholar 

  16. van Oosterom AT et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358(9291):1421–1423

    Article  PubMed  Google Scholar 

  17. Blanke CD et al (2008) Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625

    Article  CAS  PubMed  Google Scholar 

  18. Heinrich MC et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708–710

    Article  CAS  PubMed  Google Scholar 

  19. Heinrich MC et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342–4349

    Article  CAS  PubMed  Google Scholar 

  20. Antonescu CR et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11(11):4182–4190

    Article  CAS  PubMed  Google Scholar 

  21. Zalcberg JR et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41(12):1751–1757

    Article  CAS  PubMed  Google Scholar 

  22. Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338

    Article  CAS  PubMed  Google Scholar 

  23. Goodman VL et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13(5):1367–1373

    Article  CAS  PubMed  Google Scholar 

  24. DeMatteo R, Ballman K, Antonescu C et al (2009) Adjuvant Imatinib Mesylate after resection of localized primary gastrointestinal stromal tumor: a randomized double blind placebo controlled trial. Lancet 373:1097–1104

    Article  CAS  PubMed  Google Scholar 

  25. Blay JY et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25(9):1107–1113

    Article  CAS  PubMed  Google Scholar 

  26. Singer S et al (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20(18):3898–3905

    Article  CAS  PubMed  Google Scholar 

  27. Gold J, Gonen M, Gutierrez J et al (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localized primary gastroinestinal stromal tumor–a retrospective analysis. Lancet Oncol 10:1045–1052

    Article  PubMed  Google Scholar 

  28. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY (2009) Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 20(4):64–67

    PubMed  Google Scholar 

  29. NCCN. The NCCN soft tissue sarcoma clinical practice guidelines in oncology. (version 1.2009). (C) 2009 National Comprehensive Cancer Network, Inc

  30. Eisenberg B, Judson I (2004) Surgery and Imatinib in the management of GIST. Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol II(5):465–475

    Article  Google Scholar 

  31. Eisenberg B, Harris J, Blanke C, Demetri G et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary, metastatic/recurrent operable GIST–early results of RTOG. J Surg Oncol 99(1):42–47

    Article  CAS  PubMed  Google Scholar 

  32. Andtbacka R, Ng C, Scaife C, Cormier J et al (2007) Surgical resection of Gastrointestinal Stromal Tumor after treatment with Imatinib. Ann Surg Oncol 14(1):14–24

    Article  PubMed  Google Scholar 

  33. Raut C, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325–2331

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Logistical support during submission of this article was provided by Springer Healthcare LLC. This support was funded by Novartis.

Conflict of interest

Dr. Burton L. Eisenberg, MD: Novartis Advisory Board; Dr. Kerrington D. Smith, MD: None.

Author information

Authors and Affiliations

  1. Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Section of Surgical Oncology, Lebanon, NH, USA

    Burton L. Eisenberg & Kerrington D. Smith

Authors
  1. Burton L. Eisenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerrington D. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Burton L. Eisenberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenberg, B.L., Smith, K.D. Adjuvant and neoadjuvant therapy for primary GIST. Cancer Chemother Pharmacol 67 (Suppl 1), 3–8 (2011). https://doi.org/10.1007/s00280-010-1516-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1516-5

Keywords

Search

Navigation